SCHEMBL6709701

SCHEMBL6709701

COc1cccc(C(=O)C(NC(C)=O)c2ccncc2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 6/20 0.49
ROCK2 O75116 5/20 0.49
PRKG1 Q13976 3/20 0.49
PRKACA P17612 3/20 0.49
GSK3A P49840 3/20 0.49
GSK3B P49841 3/20 0.49
CHEK1 O14757 2/20 0.49
RPS6KA5 O75582 2/20 0.49
PRKCG P05129 2/20 0.49
CDK1 P06493 2/20 0.49
RPS6KB1 P23443 2/20 0.49
CDK2 P24941 2/20 0.49
MAPK1 P28482 2/20 0.49
AKT2 P31751 2/20 0.49
IRAK1 P51617 2/20 0.49
PRKX P51817 2/20 0.49
NEK4 P51957 2/20 0.49
CDK5 Q00535 2/20 0.49
PRKCQ Q04759 2/20 0.49
PRKCD Q05655 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7142373 0.79 NPC1 (0.54) ROCK1ROCK2PRKG1PRKACAGSK3A
Hydrochloric Acid SCHEMBL11490909 0.79 CES2 (0.51) ROCK1ROCK2PRKG1PRKACAGSK3A
Bromide SCHEMBL6283052 0.78 NPC1 (0.53) ROCK1ROCK2PRKG1PRKACAGSK3A
Hydrochloric Acid SCHEMBL6708543 0.78 NPC1 (0.53) ROCK1ROCK2PRKG1PRKACAGSK3A
SCHEMBL6707539 0.76 ALDH1A1 (0.48) ROCK1ROCK2PRKG1PRKACAGSK3A
SCHEMBL1398796 0.75 CES2 (0.53) KMT2AALDH1A1NPC1CES2CES1
SCHEMBL6707538 0.73 LTA4H (0.47) ROCK2CYP3A4KMT2AALDH1A1NPC1
SCHEMBL7048516 0.73 CTSS (0.54) MAPK1KMT2AALDH1A1NPC1CES2
SCHEMBL4029309 0.72 CES2 (0.77) MAPK1CYP2D6CYP3A4CYP2C9KMT2A
SCHEMBL5216406 0.72 KMT2A (0.72) CDK5CYP2D6KMT2AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040106793-A1 Oxazoles for treating cytokine mediated diseases SMITHKLINE BEECHAM CORPORATION 2004-06-03 US disclosed
EP-0727998-B1 OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORP (US) 2004-01-21 EP disclosed
EP-1306377-A2 Pyridyl-oxazoles and their use as cytokines inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2003-05-02 EP disclosed
US-20020169173-A1 Oxazoles for treating cytokine mediated diseases SMITHKLINE BEECHAM CORPORATION 2002-11-14 US disclosed
US-6288062-B1 INTERLEUKIN AND TUMOR NECROSIS FACTOR INHIBITORS; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS SMITHKLINE BEECHAM CORPORATION 2001-09-11 US disclosed
EP-0727998-A4 OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORP (US) 1997-03-19 EP disclosed
EP-0727998-A1 OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1996-08-28 EP disclosed
WO-1995013067-A1 OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1995-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106793-A1 Oxazoles for treating cytokine mediated diseases IL2, IL17A, IL5 ROCK1 2672/4885ROCK2 3627/4885PRKG1 3233/4885
US-20020169173-A1 Oxazoles for treating cytokine mediated diseases IL17A, IL4I1, IL2 ROCK1 3366/4885ROCK2 4326/4885PRKG1 4542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.